IDEXX Laboratories, Inc.

NasdaqGS:IDXX Stock Report

Market Cap: US$33.5b

IDEXX Laboratories Past Earnings Performance

Past criteria checks 3/6

IDEXX Laboratories has been growing earnings at an average annual rate of 13.1%, while the Medical Equipment industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 9.8% per year. IDEXX Laboratories's return on equity is 53.5%, and it has net margins of 22.5%.

Key information

13.1%

Earnings growth rate

13.9%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate9.8%
Return on equity53.5%
Net Margin22.5%
Next Earnings Update03 Feb 2025

Recent past performance updates

Recent updates

At US$420, Is It Time To Put IDEXX Laboratories, Inc. (NASDAQ:IDXX) On Your Watch List?

Nov 19
At US$420, Is It Time To Put IDEXX Laboratories, Inc. (NASDAQ:IDXX) On Your Watch List?

IDEXX Laboratories Q3: Weak End-Market Demand Continues

Nov 11

Investors Appear Satisfied With IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Prospects

Oct 28
Investors Appear Satisfied With IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Prospects

Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching

Oct 15
Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching

We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease

Sep 18
We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease

A Look At The Intrinsic Value Of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Sep 05
A Look At The Intrinsic Value Of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

What Is IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Share Price Doing?

Aug 20
What Is IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Share Price Doing?

IDEXX Laboratories Q2: Headwinds From Low U.S. Clinical Visits

Aug 12

A Look Into IDEXX Laboratories' (NASDAQ:IDXX) Impressive Returns On Capital

Jul 02
A Look Into IDEXX Laboratories' (NASDAQ:IDXX) Impressive Returns On Capital

Looking For Fast Growth In Healthcare? IDEXX Has You Covered

Jun 28

Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors

Jun 04
Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors

Should You Think About Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX) Now?

May 21
Should You Think About Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX) Now?

IDEXX Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

May 03
IDEXX Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

What IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) P/E Is Not Telling You

Apr 27
What IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) P/E Is Not Telling You

IDEXX Laboratories (NASDAQ:IDXX) Has A Rock Solid Balance Sheet

Apr 11
IDEXX Laboratories (NASDAQ:IDXX) Has A Rock Solid Balance Sheet

IDEXX: Strong Recurring Revenues From Consumables, Software But Overvalued (Rating Downgrade)

Apr 08

Is It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?

Jan 30
Is It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?

IDEXX Laboratories: Valuation Rerating Doesn't Seem Justified

Jan 16

Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors

Jan 15
Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors

IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Shareholders Might Be Looking For Exit

Dec 31
IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Shareholders Might Be Looking For Exit

IDEXX Laboratories: Outstanding Business, But Valuation Is Key

Aug 15

IDEXX Laboratories Stock Is Very Expensive

Aug 08

IDEXX Laboratories Non-GAAP EPS of $1.58 misses by $0.05, revenue of $860.55M misses by $1.57M

Aug 02

Revenue & Expenses Breakdown

How IDEXX Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:IDXX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 243,845866947214
30 Jun 243,785846934208
31 Mar 243,725867925199
31 Dec 233,661845902191
30 Sep 233,588823888183
30 Jun 233,514791877183
31 Mar 233,431699858259
31 Dec 223,367679851255
30 Sep 223,340670848257
30 Jun 223,309664840249
31 Mar 223,274735821164
31 Dec 213,215745796161
30 Sep 213,135757770154
30 Jun 213,047728777152
31 Mar 212,858674739146
31 Dec 202,707582735141
30 Sep 202,591497717138
30 Jun 202,475460674134
31 Mar 202,457437681135
31 Dec 192,407428669133
30 Sep 192,351423657128
30 Jun 192,291407642123
31 Mar 192,252390638120
31 Dec 182,213377632118
30 Sep 182,170330621117
30 Jun 182,117307610115
31 Mar 182,045284596112
31 Dec 171,969263575109
30 Sep 171,906277561106
30 Jun 171,862263547104
31 Mar 171,820245534102
31 Dec 161,775222522101
30 Sep 161,732214516101
30 Jun 161,690202502100
31 Mar 161,63719249399
31 Dec 151,602192482100
30 Sep 151,55417447599
30 Jun 151,53118246799
31 Mar 151,508182457100
31 Dec 141,48618244898
30 Sep 141,48819943596
30 Jun 141,44319342293
31 Mar 141,40519040989
31 Dec 131,37718840188

Quality Earnings: IDXX has high quality earnings.

Growing Profit Margin: IDXX's current net profit margins (22.5%) are lower than last year (22.9%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: IDXX's earnings have grown by 13.1% per year over the past 5 years.

Accelerating Growth: IDXX's earnings growth over the past year (5.3%) is below its 5-year average (13.1% per year).

Earnings vs Industry: IDXX earnings growth over the past year (5.3%) did not outperform the Medical Equipment industry 12.9%.

Return on Equity

High ROE: IDXX's Return on Equity (53.5%) is considered outstanding.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 12:26
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

IDEXX Laboratories, Inc. is covered by 31 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Daniel OwczarskiAvondale Partners
Ishan MajumdarBaptista Research
Balaji PrasadBarclays